<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769352</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00074523</org_study_id>
    <nct_id>NCT01769352</nct_id>
  </id_info>
  <brief_title>Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)</brief_title>
  <acronym>TEMPEST</acronym>
  <official_title>Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the change in visual acuity of patients with post
      surgical cystoid macular edema who will be treated with two different regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the mean change in BCVA over 12 weeks of Prednisolone Acetate 1% q1h (every hour) WA
      (While Awake) + Ketorolac 0.5% qid (four times a day) versus Prednisolone Acetate qid +
      Ketorolac qid for post surgical cystoid macular edema.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean change in best-corrected visual acuity (Letter Score) at Week 12 from Baseline. The Early Treatment of Diabetic Retinopathy Study (ETDRS) score is measured on a scale from 5 to 100. The higher the score on this scale, the better is the patients vision.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Central Subfield Thickness at Week 12 From Baseline</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean Change in Central Subfield Thickness (µm) at Week 12 from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Intraocular Pressure at Week 12 From Baseline</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean Change in Intraocular Pressure (IOP) at week 12 from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Best-Corrected Visual Acuity Between Week 12 and Week 48</measure>
    <time_frame>Week 12 and Week 48</time_frame>
    <description>Mean Change in Best-Corrected Visual Acuity (Letters Score) between Week 12 and Week 48. The Early Treatment of Diabetic Retinopathy Study (ETDRS) score is measured on a scale from 5 to 100. The higher the score on this scale, the better is the patients vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Central Subfield Thickness (CST) Between Week 12 and Week 48</measure>
    <time_frame>Week 12 and Week 48</time_frame>
    <description>Mean Change in Central Subfield Thickness (CST,µm) between week 12 and week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Intraocular Pressure Between Week 12 and Week 24</measure>
    <time_frame>Week 12 and Week 48</time_frame>
    <description>Mean Change in Intraocular Pressure (IOP) between week 12 and week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Post-surgical Cystoid Macular Edema (PSCME)</condition>
  <arm_group>
    <arm_group_label>PredA q1h WA + Kelac qid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PredA qid + Kelac qid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PredA + Kelac</intervention_name>
    <description>At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.</description>
    <arm_group_label>PredA q1h WA + Kelac qid</arm_group_label>
    <arm_group_label>PredA qid + Kelac qid</arm_group_label>
    <other_name>Acular, Acuvail</other_name>
    <other_name>Pred Forte, Omnipred, Pred Mild</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than or equal to 18 years

          -  Diagnosis of PSCME in study eye confirmed by FA showing leakage from retinal vessels
             resulting in pooling of dye in the fovea and Spectralis SD-OCT showing intraretinal
             fluid in or around the fovea.

          -  BCVA score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using
             the ETDRS protocol at a distance of 4 meters).

          -  In the opinion of the investigator, decreased vision in the study eye is due to foveal
             thickening from PSCME and not to any other reason.

        Exclusion Criteria:

          -  Any patient who has other retinal diseases known to cause macular edema (choroidal
             neovascularization, vein occlusion, diabetic macular edema in the study eye). Patients
             with nonexudative Age Related Macular Degeneration (ARMD) or non-proliferative
             diabetic retinopathy without macular edema can be included in the study.

          -  Other reason for decreased visual acuity (such as amblyopia, foveal atrophy, optic
             atrophy).

          -  Pre-existing diagnosis of glaucoma in the study eye

          -  Inability to comply with study or follow up procedures

          -  Pregnancy (Women of child bearing age will be asked to take a urine pregnancy test
             prior to enrolling in the study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>August 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 15, 2017</results_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystoid macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Post-Cataract Surgery CME (PredAq1h+ Kelac Qid) - Group 1</title>
          <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)
PredA + Kelac: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawal. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.</description>
        </group>
        <group group_id="P2">
          <title>Post-Cataract Surgery CME (PredA Qid + Kelac Qid) - Group 2</title>
          <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)
PredA + Kelac: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawal. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12.</description>
        </group>
        <group group_id="P3">
          <title>Post-Other Surgery CME (PredA q1h + Kelac Qid) - Group 1</title>
          <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)
PredA + Kelac: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawal. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.</description>
        </group>
        <group group_id="P4">
          <title>Post-Other Surgery CME (PredA Qid + Kelac Qid) - Group 2</title>
          <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)
PredA + Kelac: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawal. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Post-Cataract Surgery Macular Edema- Group 1</title>
          <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
        </group>
        <group group_id="B2">
          <title>Post-Cataract Surgery Macular Edema- Group 2</title>
          <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
        </group>
        <group group_id="B3">
          <title>Post-Other Surgery Macular Edema- Group 1</title>
          <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
        </group>
        <group group_id="B4">
          <title>Post-Other Surgery Macular Edema- Group 2</title>
          <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="2.0"/>
                    <measurement group_id="B2" value="69.9" spread="2.4"/>
                    <measurement group_id="B3" value="66.2" spread="1.9"/>
                    <measurement group_id="B4" value="60.1" spread="4.8"/>
                    <measurement group_id="B5" value="67.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Surgeries at the Time of Enrollment, mean+SEM</title>
          <units>surgeries</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.2"/>
                    <measurement group_id="B2" value="1.4" spread="0.2"/>
                    <measurement group_id="B3" value="2.1" spread="0.4"/>
                    <measurement group_id="B4" value="2.1" spread="0.3"/>
                    <measurement group_id="B5" value="1.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best Corrected Visual Acuity at Baseline mean+SEM (Letter Score)</title>
          <description>Best corrected visual acuity (BCVA) is a test which assesses visual acuity using an eye exam. Higher the number, better is the visual acuity and vice versa. The total score ranges from 5 to 100, with 100 representing the best visual acuity.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" lower_limit="31" upper_limit="80"/>
                    <measurement group_id="B2" value="60.9" lower_limit="29" upper_limit="75"/>
                    <measurement group_id="B3" value="53.4" lower_limit="19" upper_limit="68"/>
                    <measurement group_id="B4" value="50.9" lower_limit="20" upper_limit="73"/>
                    <measurement group_id="B5" value="55.8" lower_limit="19" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CST at Baseline, mean+SEM (µm)</title>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="515.5" spread="33.9"/>
                    <measurement group_id="B2" value="447.6" spread="33.9"/>
                    <measurement group_id="B3" value="487.3" spread="33.3"/>
                    <measurement group_id="B4" value="489.1" spread="29.5"/>
                    <measurement group_id="B5" value="485.0" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IOP at Baseline, mean+SEM (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="1.3"/>
                    <measurement group_id="B2" value="15.6" spread="0.8"/>
                    <measurement group_id="B3" value="14.8" spread="0.9"/>
                    <measurement group_id="B4" value="16.0" spread="2.2"/>
                    <measurement group_id="B5" value="15.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline</title>
        <description>Mean change in best-corrected visual acuity (Letter Score) at Week 12 from Baseline. The Early Treatment of Diabetic Retinopathy Study (ETDRS) score is measured on a scale from 5 to 100. The higher the score on this scale, the better is the patients vision.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-Cataract Surgery Macular Edema- Group 1</title>
            <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Post-Cataract Surgery Macular Edema- Group 2</title>
            <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O3">
            <title>Post-Other Surgery Macular Edema- Group 1</title>
            <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O4">
            <title>Post-Other Surgery Macular Edema- Group 2</title>
            <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline</title>
          <description>Mean change in best-corrected visual acuity (Letter Score) at Week 12 from Baseline. The Early Treatment of Diabetic Retinopathy Study (ETDRS) score is measured on a scale from 5 to 100. The higher the score on this scale, the better is the patients vision.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="2.6"/>
                    <measurement group_id="O2" value="7.8" spread="3.4"/>
                    <measurement group_id="O3" value="13.1" spread="3.4"/>
                    <measurement group_id="O4" value="9.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Central Subfield Thickness at Week 12 From Baseline</title>
        <description>Mean Change in Central Subfield Thickness (µm) at Week 12 from Baseline</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-Cataract Surgery Macular Edema- Group 1</title>
            <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Post-Cataract Surgery Macular Edema- Group 2</title>
            <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O3">
            <title>Post-Other Surgery Macular Edema- Group 1</title>
            <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O4">
            <title>Post-Other Surgery Macular Edema- Group 2</title>
            <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Central Subfield Thickness at Week 12 From Baseline</title>
          <description>Mean Change in Central Subfield Thickness (µm) at Week 12 from Baseline</description>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-152.7" spread="33.5"/>
                    <measurement group_id="O2" value="-56.4" spread="21.0"/>
                    <measurement group_id="O3" value="-25.9" spread="25.7"/>
                    <measurement group_id="O4" value="-75.0" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Intraocular Pressure at Week 12 From Baseline</title>
        <description>Mean Change in Intraocular Pressure (IOP) at week 12 from Baseline</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-Cataract Surgery Macular Edema- Group 1</title>
            <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Post-Cataract Surgery Macular Edema- Group 2</title>
            <description>Patients who developed cystoid macular edema (CME) after cataract surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O3">
            <title>Post-Other Surgery Macular Edema- Group 1</title>
            <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
          <group group_id="O4">
            <title>Post-Other Surgery Macular Edema- Group 2</title>
            <description>Patients who developed cystoid macular edema (CME) after other surgery and are started on Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hr (qid) and Ketorolac (Kelac) 0.5% ophthalmic solution four times a day (qid)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Intraocular Pressure at Week 12 From Baseline</title>
          <description>Mean Change in Intraocular Pressure (IOP) at week 12 from Baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.2"/>
                    <measurement group_id="O2" value="3.3" spread="1.4"/>
                    <measurement group_id="O3" value="0.3" spread="1.6"/>
                    <measurement group_id="O4" value="1.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Best-Corrected Visual Acuity Between Week 12 and Week 48</title>
        <description>Mean Change in Best-Corrected Visual Acuity (Letters Score) between Week 12 and Week 48. The Early Treatment of Diabetic Retinopathy Study (ETDRS) score is measured on a scale from 5 to 100. The higher the score on this scale, the better is the patients vision.</description>
        <time_frame>Week 12 and Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone Acetate Switched From 4 Hours to Every 1 Hour</title>
            <description>Patients who switched from Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hours to every 1 hour while awake at week 12.</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone Acetate Continued Every 1 Hour</title>
            <description>Patients who continued on Prednisolone Acetate (PredA) 1% ophthalmic solution continued every 1 hour while awake at week 12.</description>
          </group>
          <group group_id="O3">
            <title>Prednisolone Acetate Switched From Every 1 Hour to 4 Hours</title>
            <description>Patients who switched from Prednisolone Acetate (PredA) 1% ophthalmic solution from every 1 hours while awake to every 4 hours at week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best-Corrected Visual Acuity Between Week 12 and Week 48</title>
          <description>Mean Change in Best-Corrected Visual Acuity (Letters Score) between Week 12 and Week 48. The Early Treatment of Diabetic Retinopathy Study (ETDRS) score is measured on a scale from 5 to 100. The higher the score on this scale, the better is the patients vision.</description>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="2.5"/>
                    <measurement group_id="O2" value="5.4" spread="2.1"/>
                    <measurement group_id="O3" value="10.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Central Subfield Thickness (CST) Between Week 12 and Week 48</title>
        <description>Mean Change in Central Subfield Thickness (CST,µm) between week 12 and week 48</description>
        <time_frame>Week 12 and Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone Acetate Switched From 4 Hours to Every 1 Hour</title>
            <description>Patients who switched from Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hours to every 1 hour while awake at week 12.</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone Acetate Continued Every 1 Hour</title>
            <description>Patients who continued on Prednisolone Acetate (PredA) 1% ophthalmic solution continued every 1 hour while awake at week 12.</description>
          </group>
          <group group_id="O3">
            <title>Prednisolone Acetate Switched From Every 1 Hour to 4 Hours</title>
            <description>Patients who switched from Prednisolone Acetate (PredA) 1% ophthalmic solution from every 1 hours while awake to every 4 hours at week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Central Subfield Thickness (CST) Between Week 12 and Week 48</title>
          <description>Mean Change in Central Subfield Thickness (CST,µm) between week 12 and week 48</description>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-109.7" spread="50.9"/>
                    <measurement group_id="O2" value="-44.0" spread="20.8"/>
                    <measurement group_id="O3" value="-1.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Intraocular Pressure Between Week 12 and Week 24</title>
        <description>Mean Change in Intraocular Pressure (IOP) between week 12 and week 24</description>
        <time_frame>Week 12 and Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone Acetate Switched From 4 Hours to Every 1 Hour</title>
            <description>Patients who switched from Prednisolone acetate (PredA) 1% ophthalmic solution every 4 hours to every 1 hour while awake at week 12.</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone Acetate Continued Every 1 Hour</title>
            <description>Patients who continued on Prednisolone Acetate (PredA) 1% ophthalmic solution continued every 1 hour while awake at week 12.</description>
          </group>
          <group group_id="O3">
            <title>Prednisolone Acetate Switched From Every 1 Hour to 4 Hours</title>
            <description>Patients who switched from Prednisolone Acetate (PredA) 1% ophthalmic solution from every 1 hours while awake to every 4 hours at week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Intraocular Pressure Between Week 12 and Week 24</title>
          <description>Mean Change in Intraocular Pressure (IOP) between week 12 and week 24</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.5"/>
                    <measurement group_id="O2" value="0.0" spread="1.7"/>
                    <measurement group_id="O3" value="-4.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prednisolone Acetate Every 1 Hour While Awake (Group 1)</title>
          <description>Patients who were given Prednisolone Acetate (PredA) 1% ophthalmic solution every 1 hour while awake.
Adverse events are dose dependent and they don't depend on the type of surgery patient underwent previously. Therefore both, post-cataract surgery macular edema and post-other surgery macular edema adverse events were clumped together for patients who received PredA every 1 hour (q1h) - Group 1.</description>
        </group>
        <group group_id="E2">
          <title>Prednisolone Acetate Four Times a Day (Group 2)</title>
          <description>Patients who were given Prednisolone Acetate (PredA) 1% ophthalmic solution four times a day
Adverse events are dose dependent and they don't depend on the type of surgery patient underwent previously. Therefore both, post-cataract surgery macular edema and post-other surgery macular edema adverse events were clumped together for patients who received PredA four times a day (qid) - Group 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood transfusion due to severe anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cataract Surgery due to progression of cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure Lowering Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Surgery for resection of Zenker's Diverticulum</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Periodontal surgery</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in Intraocular Pressure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infections</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter A. Campochiaro</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-955-5106</phone>
      <email>pcampo@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

